Response to Comments: MolDX: Breast Cancer Index® (BCI) Gene Expression Test

This document is a response to comments for the MolDX: Breast Cancer Index® (BCI) Gene Expression Test Local Coverage Determination (LCD L37832). The public comment period was 05/28/2020–07/12/2020; the notice period begins 03/18/2021 and the LCD becomes effective 05/02/2021. The text provided contains administrative metadata about the comment/notice period and does not itself state clinical coverage criteria, limitations, documentation requirements, or frequency limits.